Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards

Life Health > Health Insurance

Drug makers' popularity falls

Your article was successfully shared with the contacts you provided.

Gallup has come out with new survey data suggesting that health insurers’ efforts to talk about the effects of higher prescription drug prices on health care costs may be paying off.

See also: Health insurers may be outcharming drug makers

The percentage of Americans the organization surveyed in August who said they had a positive opinion of the pharmaceutical industry dropped to 35 percent, from 40 percent, and the percentage with a negative view increased to 43 percent, from 36 percent.

Jim Norman, a Gallup analyst, computed a net view index by subtracting from the negative view level from the positive view level.

The negative 8 percent net view is down from a positive 4 percent net view in 2014, but up from 10 percent in 2013.

Americans’ net view level for the industry hovered under negative 15 perent for most of the period from 2004 through 2010, after the rollout of the Medicare Part D prescription drug program.

America’s Health Insurance Plan (AHIP) has been making a concerted effort to talk about the impact of new drugs for conditions such as hepatitis C that can cost more than $10,000 per month.

See also: Cancer is getting more expensive, forcing doctors to take notice

The pharmaceutical manufacturers have defended themselves by pointing to the high cost of drug research, the high risk of failure, and the benefits effective drugs can have on improving the quality of patients’ lives.

See also: Roche CEO slams ‘stupid’ U.K. decision to drop some cancer drugs


© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.